Search clinical trials for: 2nd Line

Total 9756 results

Hellenic Oncology Research Group

Completed

Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer

Ovarian Cancer

Greece
Zhejiang Cancer Hospital

Unknown

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Breast Cancer

China
Novartis Pharmaceuticals

Completed

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Gastrointestinal Stromal Tumors (GIST)

Israel
Hoffmann-La Roche

Completed

Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer (AVALANCHE)

Carcinoma, Non-Small-Cell Lung

Hungary
Asbestos Diseases Research Foundation
EnGeneIC Limited

Completed

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Australia
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

Pancreatic Cancer | Liver Cancer

United States
Boehringer Ingelheim

Completed

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Carcinoma, Non-Small-Cell Lung

Germany, Canada, United States, Hong Kong, Taiwan, Brazil, Korea, Republic of, Peru, Poland, Ukraine, Thailand, Argentina, Australia, New Zealand, Sweden, Hungary, Turkey, Serbia, Bosnia and Herzegovina, Chile, Colombia, Ecuador, Ir... and more
US Oncology Research
Eli Lilly and Company; Oregon Health and Science University

Completed

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

Androgen-independent Prostate Cancer

United States
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
NantCell, Inc.

Completed

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Italy, France, Russian Federation, Spain, Hungary, Poland, Singapore, Hong Kong, India
Achieve Life Sciences

Completed

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

Prostate Cancer

France, United States, Canada, Australia, Hungary, Czech Republic, Russian Federation, United Kingdom
Optimata Ltd.

Unknown

Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy

Melanoma

Israel
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Breast Cancer

Greece
Cantonal Hospital of St. Gallen
Celgene Corporation; Amgen; Mundipharma Medical Company; Mundipharma Research GmbH...

Completed

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

Multiple Myeloma

Switzerland
ANRS, Emerging Infectious Diseases

Completed

National Evaluation of PI-based 2nd Line Efficacy in Cambodia

HIV

Cambodia
Hoffmann-La Roche

Completed

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Estonia, Hungary, Turkey, Israel, Slovakia, Bulgaria, Lithuania, Macedonia, The Former Yugoslav Republic of
Tianjin Medical University Cancer Institute and...

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
University Hospital, Angers

Unknown

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 (CBPC)

Small Cell Lung Cancer

France
Novartis Pharmaceuticals

Completed

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Non-small-cell Lung Cancer

Canada, France, Spain, Netherlands, Singapore, Germany, Korea, Republic of, Turkey, United States, Norway
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
Bristol-Myers Squibb

Completed

Phase II, 2nd Line Melanoma - RAND Monotherapy

Melanoma

France, Italy, United States, Germany, Canada, Denmark
Hellenic Oncology Research Group

Completed

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

SCLC

Greece
Hellenic Oncology Research Group

Completed

Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer

Metastatic Breast Cancer

Greece
Hellenic Oncology Research Group

Completed

Cabazitaxel in Relapsed and Metastatic NSCLC

NSCLC

Greece
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

Greece
AstraZeneca
Parexel

Withdrawn

T790M Mutation Positive 2nd Line STandard of cAre Registry (T-STAR)

Non Small Cell Lung Cancer

Italy, Russian Federation, Spain, China, Netherlands, United States, Taiwan, France, Germany
University of Roma La Sapienza

Unknown

Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

Cirrhosis

Italy
Seoul National University Hospital

Completed

Paclitaxel and Irinotecan in Advanced Gastric Cancer (TI-2ndAGC)

Advanced Gastric Cancer

Korea, Republic of
Sanofi

Completed

Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

Pancreatic Neoplasms

Canada
Hellenic Oncology Research Group

Completed

Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer

Metastatic Colorectal Cancer

Greece
Hellenic Oncology Research Group

Completed

Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment

Non Small Cell Lung Cancer

Greece
Accelerated Community Oncology Research Network
Bristol-Myers Squibb

Completed

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Metastatic Breast Cancer

United States
OHSU Knight Cancer Institute
Genentech, Inc.; OSI Pharmaceuticals

Terminated

Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (CHANGE)

Squamous Cell Carcinoma of the Head and Neck

China, Korea, Republic of
Accelerated Community Oncology Research Network
Amgen

Completed

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Breast Cancer

United States
EMD Serono

Completed

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Non-Small Cell Lung Cancer

United States
Spanish Cooperative Group for the Treatment of...
Amgen

Completed

Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Metastatic Colorectal Cancer

Spain
Cancer Institute and Hospital, Chinese Academy...
Chinese PLA General Hospital; Peking University Cancer Hospital & Institute; Tianjin... and other collaborators

Unknown

Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

Breast Cancer

China
AIO-Studien-gGmbH
iOMEDICO AG

Terminated

Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer (VOXEL)

Colorectal Neoplasms

Germany
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Colorectal Cancer

Greece
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Colorectal Cancer

Greece
Achieve Life Sciences

Completed

Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC

Prostate Cancer

Canada
AstraZeneca

Completed

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Cancer

Taiwan
Eli Lilly and Company

Completed

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Lung Neoplasms

United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

Metastatic Breast Cancer
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Breast Cancer

Greece
Hung-Hsueh Chou
Bristol-Myers Squibb; GlaxoSmithKline

Unknown

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Recurrent Endometrial Cancer
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV

Non Small Cell Lung Cancer

Greece
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

Ovarian Cancer

Greece

3

Subscribe